Sanofi

• 04/09/2025

  Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

  Inside information
• 29/08/2025

  Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

  Inside information⇄FR
• 14/08/2025

  Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

  Inside information⇄FR
• 06/08/2025

  Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

  Inside information⇄FR
• 31/07/2025

  Press release: Online availability of Sanofi’s half-year financial report for 2025

  Inside information⇄FR
• 31/07/2025

  Communiqué de presse : T2 : croissance à deux chiffres desventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre

  Inside informationFrench
• 30/07/2025

  Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

  Inside information⇄FR
• 25/07/2025

  Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

  Inside information⇄FR
• 22/07/2025

  Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline

  Inside information⇄FR
• 18/07/2025

  Press Release: Sanofi completes acquisition of Blueprint Medicines

  Inside information⇄FR
• 17/07/2025

  Communiqué de presse : Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint

  Inside informationFrench
• 16/07/2025

  Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

  Inside information⇄FR
• 30/06/2025

  Press release: Availability of the Q2 2025 Aide mémoire

  Inside information⇄FR
• 30/06/2025

  Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

  Inside information⇄FR
• 25/06/2025

  Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

  Inside information⇄FR
• 23/06/2025

  Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

  Inside information⇄FR
• 20/06/2025

  Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

  Inside information⇄FR
• 17/06/2025

  Press release: Sanofi successfully prices €1.5 billion bond issue

  Inside information⇄FR
• 15/06/2025

  Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

  Inside information⇄FR
• 09/06/2025

  Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

  Inside information⇄FR
• 05/06/2025

  Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

  Inside information⇄FR
• 03/06/2025

  Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

  Inside information⇄FR
• 03/06/2025

  Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

  Inside information⇄FR
• 02/06/2025

  Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

  Inside information⇄FR
• 30/05/2025

  Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

  Inside information⇄FR
• 29/05/2025

  Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

  Inside information⇄FR
• 27/05/2025

  Press Release: Sanofi completes acquisition of DR-0201

  Inside information⇄FR
• 22/05/2025

  Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

  Inside information⇄FR
• 30/04/2025

  Press Release: Annual General Meeting of April 30, 2025

  Inside information⇄FR
• 30/04/2025

  Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

  Inside information⇄FR
• 24/04/2025

  Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

  Inside information⇄FR
• 18/04/2025

  Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

  Inside information⇄FR
• 15/04/2025

  Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

  Inside information⇄FR
• 08/04/2025

  Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

  Inside information⇄FR
• 03/04/2025

  Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

  Inside information⇄FR
• 28/03/2025

  Communiqué de presse : Qfitlia – premier médicament approuvé aux États-Unis pour le traitement des hémophilies A ou B, avec ou sans inhibiteurs

  Inside informationFrench
• 28/03/2025

  Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

  Inside information⇄FR
• 26/03/2025

  Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

  Inside information⇄FR
• 25/03/2025

  Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

  Inside information⇄FR
• 24/03/2025

  Press Release: Availability of the Q1 2025 Aide mémoire

  Inside information⇄FR
• 20/03/2025

  Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

  Inside information⇄FR
• 08/03/2025

  Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

  Inside information
• 05/03/2025

  Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

  Inside information

ISIN

FR0000120578

Ticker

SAN

LEI

549300E9PC51EN656011

Sector

Health care

Founded

2004

Employees

106,566

Country of registration

FR

Last filing

04/08/2026, 07:00

Description from Wikidata, CC0 licence.

• ACAccorCAC 40
• CECellectis
• SASociete Anonyme des Bains de Mer et du Cercle des Etrangers A Monaco
• IPIpsen SA
• CACarbios
• NONovacyt